• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients.

作者信息

Vigara Luis Alberto, Villanego Florentino, Orellana Cristhian, Naranjo Javier, Torrado Julia, Garcia Teresa, Mazuecos Auxiliadora

机构信息

Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain.

出版信息

Clin Transplant. 2022 May;36(5):e14633. doi: 10.1111/ctr.14633. Epub 2022 Mar 13.

DOI:10.1111/ctr.14633
PMID:35258121
Abstract
摘要

相似文献

1
Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients.胰高血糖素样肽-1受体激动剂在一组肾移植受者中的有效性和安全性。
Clin Transplant. 2022 May;36(5):e14633. doi: 10.1111/ctr.14633. Epub 2022 Mar 13.
2
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.新型抗糖尿病药物在肾移植受者糖尿病管理中的应用评价。
Ann Pharmacother. 2021 Apr;55(4):496-508. doi: 10.1177/1060028020951955. Epub 2020 Aug 14.
3
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
4
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.使用基础胰岛素和胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病，以满足未被满足的治疗需求
J Fam Pract. 2017 Oct;66(10 Suppl):S17-S28.
5
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
6
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.胰高血糖素样肽-1及其受体激动剂：它们在2型糖尿病管理中的作用。
Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15.
7
Glucagon-like peptide-1 receptor analogues in renal transplant recipients with diabetes: Medium term follow of patients from a single UK centre.糖尿病肾移植受者中胰高血糖素样肽-1受体类似物：来自英国单一中心患者的中期随访
Diabet Med. 2023 May;40(5):e15057. doi: 10.1111/dme.15057. Epub 2023 Feb 10.
8
GLP-1 receptor agonist confer target organ protection in type 2 diabetes.胰高血糖素样肽-1受体激动剂对2型糖尿病患者的靶器官具有保护作用。
Diabetes Metab. 2017 Apr;43 Suppl 1:2S1-2S2. doi: 10.1016/S1262-3636(17)30066-6.
9
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.胰高血糖素样肽-1受体激动剂在2型糖尿病中的治疗潜力：综述
Expert Rev Clin Pharmacol. 2016;9(2):241-65. doi: 10.1586/17512433.2016.1121808. Epub 2016 Jan 8.
10
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。
Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.

引用本文的文献

1
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study.胰高血糖素样肽-1受体激动剂在已有糖尿病的肾移植受者中的应用：一项回顾性队列研究
Lancet Diabetes Endocrinol. 2025 May;13(5):374-383. doi: 10.1016/S2213-8587(24)00371-1. Epub 2025 Mar 5.
2
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.胰高血糖素样肽-1受体激动剂与2型糖尿病肾移植受者心血管及肾脏结局的关联
Cardiovasc Diabetol. 2025 Feb 21;24(1):87. doi: 10.1186/s12933-025-02649-0.
3
GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum.
胰高血糖素样肽-1激动剂用于肾移植受者：对当前证据及整个研究领域未来方向的叙述性综述
Can J Kidney Health Dis. 2024 Oct 31;11:20543581241290317. doi: 10.1177/20543581241290317. eCollection 2024.
4
Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence.钠-葡萄糖转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在糖尿病肾移植受者中的安全性和有效性：证据综述
J Clin Med. 2024 Oct 17;13(20):6181. doi: 10.3390/jcm13206181.
5
Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂在肾移植受者中的安全性和有效性：一项系统评价和荟萃分析。
Clin Kidney J. 2024 Feb 2;17(2):sfae018. doi: 10.1093/ckj/sfae018. eCollection 2024 Feb.
6
Diabetic Kidney Disease in Post-Kidney Transplant Patients.肾移植术后患者的糖尿病肾病
J Clin Med. 2024 Jan 30;13(3):793. doi: 10.3390/jcm13030793.
7
International consensus on post-transplantation diabetes mellitus.移植后糖尿病的国际共识。
Nephrol Dial Transplant. 2024 Feb 28;39(3):531-549. doi: 10.1093/ndt/gfad258.
8
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review.用于糖尿病肾移植患者管理的新型药物：文献综述
Life (Basel). 2023 May 26;13(6):1265. doi: 10.3390/life13061265.